stockrow
Friday 6 November 2026
Export VMD’s income statement to Excel — free account
Viemed Healthcare, Inc.
VMD Healthcare Medical Devices
Viemed Healthcare, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $270.3 million, up 20.5% from fiscal 2024.
- Revenue
- +12.2%
- EPS
- +38.1%
- Free cash flow
- −67.6%
- Total debt
- −62.8%
Quarter to September 2026, against a year earlier
9.18
0.17
+1.89%
Follow VMD
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
21.96 | 30.00 | 23.62 | 19.05 |
+8 more quarters Free account |
P/S ratio |
1.12 | 1.45 | 1.24 | 1.07 | |
P/FCF ratio |
22.77 | 18.47 | 13.87 | 16.75 | |
P/Operating CF |
30.18 | 27.42 | 43.85 | 0.00 | |
P/B ratio |
2.28 | 2.99 | 2.43 | 2.01 | |
Price to Tangible BV |
3.77 | 5.08 | 4.13 | 3.47 | |
EV/Sales |
1.11 | 1.43 | 1.23 | 1.07 | |
EV/EBITDA |
7.10 | 9.17 | 7.70 | 6.97 | |
EV/Operating CF |
9.73 | 10.21 | 9.13 | 8.67 | |
EV/FCF |
22.65 | 18.32 | 13.85 | 16.82 | |
Quick Ratio |
0.94 | 0.90 | 1.01 | 0.96 | |
Current Ratio |
1.25 | 1.13 | 1.22 | 1.18 | |
Net Debt/EBITDA |
(0.12) | (0.29) | (0.05) | 0.14 | |
Debt/Assets |
3.78% | 3.47% | 4.66% | 7.40% | |
Debt/Equity |
0.05 | 0.05 | 0.06 | 0.10 | |
Asset Turnover |
1.51 | 1.55 | 1.53 | 1.44 | |
Operating CF/Net income |
2.48 | 5.75 | 3.13 | 0.00 | |
Capex/Depreciation |
(0.96) | (0.96) | (0.71) | 0.00 | |
Interest Coverage |
41.33 | 20.13 | 15.14 | 23.62 | |
Research and Development Expense of Revenue |
0.62% | 0.65% | 0.77% | 0.78% | |
Selling, General and Administrative Expense of Revenue |
47.08% | 50.15% | 49.38% | 45.31% | |
Intangible Assets out of Total Assets |
0.29 | 0.29 | 0.30 | 0.30 | |
Share Based Compensation of Revenue |
3.07% | 2.60% | 3.25% | 0.00% | |
Graham Net Nets |
0.01 | (0.01) | 0.00 | (0.02) | |
Graham Number |
6.10 | 5.71 | 5.77 | 5.69 | |
Earnings Yield |
4.55% | 3.33% | 4.23% | 5.25% | |
Free Cash Flow Yield |
4.39% | 5.41% | 7.21% | 5.97% | |
Revenue per Share |
2.12 | 2.04 | 1.96 | 1.96 | |
Operating CF per Share |
0.30 | 0.42 | 0.21 | 0.00 | |
Capex per Share |
(0.20) | (0.19) | (0.14) | 0.00 | |
Free Cash Flow per Share |
0.11 | 0.23 | 0.07 | 0.00 | |
Cash per Share |
0.25 | 0.28 | 0.25 | 0.35 | |
Shareholders Equity per Share |
3.99 | 3.82 | 3.79 | 3.69 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.99 | 3.82 | 3.79 | 3.69 | |
Free Cash Flow |
4.03 | 8.62 | 2.59 | 0.00 | |
Working Capital |
11.97 | 6.07 | 9.11 | 7.44 | |
Capital Expenditures |
(7.46) | (7.29) | (5.48) | 0.00 | |
Net Current Asset Value |
3.64 | (4.29) | (1.75) | (7.14) | |
EV/EBIT |
13.51 | 17.81 | 14.92 | 14.19 | |
Capex to Sales |
0.09 | 0.09 | 0.07 | 0.00 | |
Price to Operating Income |
13.59 | 17.96 | 14.95 | 14.13 | |
| Other line items | |||||
Average Receivables |
32.11 | 29.39 | 28.98 | 25.36 | |
Average Payables |
9.65 | 9.62 | 8.26 | 6.33 | |
Average Inventory |
4.91 | 4.80 | 4.85 | 4.68 | |
Average Assets |
205.00 | 194.41 | 187.72 | 188.11 | |
Average Common Equity |
143.74 | 143.79 | 141.27 | 138.41 |
Columns are period end dates · fundamentals updated 6 Nov 2026